In line with these observations, evidence of ALT is observed in a subset (∼15%) of HER2-enriched breast cancer patients who presented with lymph node metastases at the time of initial diagnosis and ultimately succumbed to highly aggressive disease (Subhawong et al, 2009). This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.